ESR1 and breast cancer: Results from preclinical models have shown that adaptive therapy with dose modulation was able to achieve indefinite control in mouse xenografts of metastatic triple-negative (MDA-MD-231) and estrogen-receptor-positive (ER+) (MCF7) breast cancer [2,4,8] as well as xenografts of ovarian cancer (OVCAR3) [4].